학술논문

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
Document Type
article
Source
Cancer Discovery. 10(3)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Immunology
Rare Diseases
Pancreatic Cancer
Clinical Research
Digestive Diseases
Cancer
2.1 Biological and endogenous factors
Aetiology
Animals
Carcinogenesis
Chemokine CCL3
Chemokine CCL8
Chemokines
CC
Disease Models
Animal
Fibroblasts
Humans
Mice
Pancreas
Pancreatic Neoplasms
Receptors
CCR1
T-Lymphocytes
Regulatory
Transforming Growth Factor beta
Tumor Microenvironment
Biochemistry and cell biology
Oncology and carcinogenesis
Language
Abstract
Regulatory T cells (Treg) are abundant in human and mouse pancreatic cancer. To understand the contribution to the immunosuppressive microenvironment, we depleted Tregs in a mouse model of pancreatic cancer. Contrary to our expectations, Treg depletion failed to relieve immunosuppression and led to accelerated tumor progression. We show that Tregs are a key source of TGFβ ligands and, accordingly, their depletion reprogramed the fibroblast population, with loss of tumor-restraining, smooth muscle actin-expressing fibroblasts. Conversely, we observed an increase in chemokines Ccl3, Ccl6, and Ccl8 leading to increased myeloid cell recruitment, restoration of immune suppression, and promotion of carcinogenesis, an effect that was inhibited by blockade of the common CCL3/6/8 receptor CCR1. Further, Treg depletion unleashed pathologic CD4+ T-cell responses. Our data point to new mechanisms regulating fibroblast differentiation in pancreatic cancer and support the notion that fibroblasts are a heterogeneous population with different and opposing functions in pancreatic carcinogenesis. SIGNIFICANCE: Here, we describe an unexpected cross-talk between Tregs and fibroblasts in pancreatic cancer. Treg depletion resulted in differentiation of inflammatory fibroblast subsets, in turn driving infiltration of myeloid cells through CCR1, thus uncovering a potentially new therapeutic approach to relieve immunosuppression in pancreatic cancer.See related commentary by Aykut et al., p. 345.This article is highlighted in the In This Issue feature, p. 327.